Effects of crisaborole topical: A Synthesis of Findings from 5 Studies

  1. Home
  2. Effects of crisaborole topical
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of crisaborole topical: A Synthesis of Findings from 5 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of crisaborole topical: A Synthesis of Findings from 5 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Crisaborole topical ointment is a novel, boron-based, small-molecule, topical phosphodiesterase-4 inhibitor that has been shown to be effective in treating mild to moderate atopic dermatitis (AD) in several clinical trials. 5 , 4 , 3 , 1 These studies demonstrated that crisaborole topical ointment improved itching and skin symptoms in patients with AD. 5 , 4 , 3 , 1 Furthermore, crisaborole topical ointment was well-tolerated, even when applied to sensitive skin areas. 2 , 1 , 3

Benefits and risks

Benefits summary

Crisaborole topical ointment is a potential treatment option for patients with mild to moderate AD, as it has been shown to improve itching and skin symptoms. 5 , 4 , 3 , 1 Compared to other AD treatments, crisaborole topical ointment may have a lower risk of side effects such as skin thinning. 1

Risks summary

Crisaborole topical ointment is generally well-tolerated, and serious side effects have not been reported. 2 , 5 , 4 , 3 , 1 However, some patients may experience mild skin irritation, dryness, or redness. 2 , 5 , 4 , 3 , 1

Study comparisons

Study similarities

These studies consistently demonstrated that crisaborole topical ointment is an effective and safe treatment option for patients with mild to moderate AD. 5 , 4 , 3 , 1 Across all studies, crisaborole topical ointment improved itching and skin symptoms and was well-tolerated. 5 , 4 , 3 , 1

Study differences

These studies varied in terms of the concentration of crisaborole topical ointment used, the age range of participants, and study design. 5 , 4 , 3 , 1 For example, the study in 5 involved the use of 2% crisaborole topical ointment in adult patients, while the study in 4 involved the use of 0.5% or 2% crisaborole topical ointment in adolescent patients. 5 , 4

Consistency and inconsistencies of findings

The findings of these studies suggest that crisaborole topical ointment is an effective and safe treatment option for patients with mild to moderate AD. 5 , 4 , 3 , 1 However, further research is needed to assess the long-term effects of crisaborole topical ointment and to compare it to other AD treatments. 5 , 4 , 3 , 1

Practical implications and considerations

Crisaborole topical ointment may be a helpful treatment option for patients with mild to moderate AD, as it has been shown to improve itching and skin symptoms. 5 , 4 , 3 , 1 However, it is important to note that crisaborole topical ointment may not be effective for all patients with AD. 5 , 4 , 3 , 1 Additionally, crisaborole topical ointment should be used as directed by a healthcare professional. 5 , 4 , 3 , 1

Limitations of current research

These studies have limitations, including the need for further research to assess the long-term effects of crisaborole topical ointment and to compare it to other AD treatments. 5 , 4 , 3 , 1 Additionally, these studies were limited to specific age groups and severity of AD, so further research is needed to evaluate the effectiveness of crisaborole topical ointment in a broader range of patients. 5 , 4 , 3 , 1

Future directions for research

Further research is needed to assess the long-term effects of crisaborole topical ointment and to compare it to other AD treatments. 5 , 4 , 3 , 1 Additionally, further research is needed to evaluate the effectiveness of crisaborole topical ointment in a broader range of patients. 5 , 4 , 3 , 1

Conclusion

Crisaborole topical ointment is considered to be an effective and safe treatment option for patients with mild to moderate AD. 5 , 4 , 3 , 1 However, further research is needed to assess the long-term effects of crisaborole topical ointment and to compare it to other AD treatments. 5 , 4 , 3 , 1 If you are struggling with the symptoms of AD, it is important to speak to a healthcare professional to determine the best treatment option for you. 5 , 4 , 3 , 1

Literature analysis of 5 papers
Positive Content
5
Neutral Content
0
Negative Content
0
Article Type
3
0
0
1
5
1.

2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.

Author: CheapeAlice C, MurrellDedee F

Atopic dermatitis treatment

Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. So far, 7 trials have been completed in atopic dermatitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers.

Author: ZaneLee T, HughesMatilda H, ShakibSepehr

Well-tolerated

Crisaborole topical ointment was well-tolerated when applied to sensitive skin areas in healthy volunteers, suggesting its potential use as a topical treatment for atopic dermatitis (AD) and psoriasis.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.

Author: ZaneLee T, KircikLeon, CallRobert, TschenEduardo, DraelosZoe Diana, ChandaSanjay, Van SyocMerrie, HebertAdelaide A

AD treatment

Crisaborole topical ointment, 2%, a PDE4 inhibitor, was evaluated in children with mild to moderate AD. The study found it to be safe and effective, with a favorable pharmacokinetic profile.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

4.

A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.

Author: Stein GoldLinda F, SpelmanLynda, SpellmanMary C, HughesMatilda H, ZaneLee T

Improved AD severity
Lesion clearance
Application site reactions

Crisaborole topical ointment 2% applied twice daily demonstrated efficacy and safety in adolescents with mild to moderate atopic dermatitis, improving AD severity index scores and achieving clearance of target lesions in a significant proportion of patients.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.

Author: MurrellDedee F, GebauerKurt, SpelmanLynda, ZaneLee T

AD treatment

Crisaborole topical ointment, 2% is a new treatment for mild to moderate atopic dermatitis. This proof-of-concept study found that crisaborole was effective and safe in adults.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.